Key result
Empagliflozin significantly reduced the index of cardio-electrophysiological balance (iCEB) from 4.24 at baseline to 3.92 at 3 months (p=0.009) in patients with T2DM without heart failure.
Why the study?
The effect of empagliflozin on arrhythmias has not been adequately studied.
Does empagliflozin improve the index of cardio-electrophysiological balance in patients with type 2 diabetes mellitus without heart failure?
Cohort (n=70)
Does empagliflozin improve the index of cardio-electrophysiological balance in patients with type 2 diabetes mellitus without heart failure?
Absolute Event Rate: 3.92% vs 4.24%
p-value: p=0.009
Empagliflozin treatment for 3 months significantly decreased iCEB and iCEBc values in patients with T2DM without HF, suggesting a potential reduction in ventricular arrhythmia risk.
May indicate lower arrhythmia risk in T2DM without HF; hypothesis-generating pending randomized confirmation.
BACKGROUND: Empagliflozin is a new antidiabetic drug with positive effects on glucose regulation and the prevention of cardiovascular diseases (CVD). The effect of empagliflozin on arrhythmias has not been adequately studied. The index of cardio-electrophysiological balance (iCEB) is a popular marker used to predict ventricular arrhythmias. Therefore, in our study, we aimed to examine the effect of empagliflozin on iCEB and iCEBc in patients with type 2 diabetes mellitus (T2DM) without heart failure (HF). METHODS: A total of 70 patients were included in the study prospectively. Electrocardiographic and echocardiographic evaluations of all patients were reviewed at baseline and the end of the third month. RESULTS: The median age of the patients was 57 (43-68 IQR), and 30 (42.9%) were male. Tp-e (100 [88-120] vs. 94 [82-105], p = .01), Tp-e/QT (0.27 [0.25-0.33] vs. 0.25 [0.23-0.30], p = .001) were significantly shorter after treatment. iCEB (4.24 [3.8-4.5] vs. 3.92 [3.79-4.42], p = .009) and iCEBc (4.78 [4.25-4.92] vs. 4.48 [4.0-4.71], p = .001) values decreased significantly after treatment compared to baseline. CONCLUSIONS: Tp-e, Tp-e/QT, iCEB, and iCEBc values decreased within physiological limits in patients with T2DM without HF. This result may be associated with a reduced risk of potential ventricular arrhythmias.
No takes yet. Share an insight, caveat, or question.
İnci et al. (2022) conducted a cohort in Type 2 diabetes mellitus without heart failure (n=70). Empagliflozin vs. Baseline was evaluated on Index of cardio-electrophysiological balance (iCEB) (p=0.009). Empagliflozin significantly reduced the index of cardio-electrophysiological balance (iCEB) from 4.24 at baseline to 3.92 at 3 months (p=0.009) in patients with T2DM without heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: